Cargando…

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

The objective of this study was to evaluate whether combinations of sulbactam, meropenem, and polymyxin-B could reduce or close the gap of mutant selection window (MSW) of individual antibiotics against Acinetobacter baumannii harboring OXA-23. MICs of three antimicrobials used alone and in combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiayuan, Diao, Shuo, Liu, Yanfei, Wang, Hongxiang, Liu, Yuwei, Zhu, Shixing, Feng, Kun, Tang, Xiaoqian, Oo, Charles, Zhu, Peijuan, Lv, Zhihua, Yu, Mingming, Sy, Sherwin K. B., Zhu, Yuanqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723340/ https://www.ncbi.nlm.nih.gov/pubmed/36483204 http://dx.doi.org/10.3389/fmicb.2022.1024702

Ejemplares similares

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2023)

Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy
por: Fedrigo, Nayara Helisandra, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae
por: Zhang, Jiayuan, et al.
Publicado: (2023)

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
por: Cedano, Jose, et al.
Publicado: (2022)

Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022)

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates
por: Pasteran, Fernando, et al.
Publicado: (2021)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023)

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii
por: Zhang, Hui, et al.
Publicado: (2021)

Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
por: Leelasupasri, Sombat, et al.
Publicado: (2018)

Impact of minocycline, polymyxin B, meropenem, and amikacin on growth-prevention of Acinetobacter baumannii with various biofilm-forming capabilities
por: Beganovic, Maya, et al.
Publicado: (2017)

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2021)

Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii
por: Onita, Tetsushu, et al.
Publicado: (2023)

Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations
por: Wences, Marisol, et al.
Publicado: (2022)

Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
por: Saelim, Weerayuth, et al.
Publicado: (2021)

Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii
por: Kanchanasuwan, Siripen, et al.
Publicado: (2021)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
por: Gill, Christian M, et al.
Publicado: (2023)

Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
por: Park, So Yeon, et al.
Publicado: (2019)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
por: Petropoulou, Dimitra, et al.
Publicado: (2022)

Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection
por: Fetiye, Kolayli, et al.
Publicado: (2004)

Clinical Outcomes Of Colistin In Combination With Either 6-G Sulbactam Or Carbapenems For The Treatment Of Extensively Drug-Resistant Acinetobacter Baumannii Pneumonia With High MIC To Sulbactam, A Prospective Cohort Study
por: Ungthammakhun, Chutchawan, et al.
Publicado: (2019)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
por: Segatore, Bernardetta, et al.
Publicado: (2022)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
por: Barin, Juliana, et al.
Publicado: (2013)

Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii
por: Temocin, Fatih, et al.
Publicado: (2015)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022)

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
por: Lim, Tze-Peng, et al.
Publicado: (2011)

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii [Corrigendum]
Publicado: (2021)

Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model
por: Fan, Bing, et al.
Publicado: (2016)

The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
por: de Oliveira, Maura S., et al.
Publicado: (2013)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
por: Lyu, Cheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_70260rfjd0cs4pcidosa1porff